Acquired Amegakaryocytic Thrombocytopenia Overview

Save information for later
Sign Up

Learn About Acquired Amegakaryocytic Thrombocytopenia

Who are the top Acquired Amegakaryocytic Thrombocytopenia Local Doctors?
Distinguished in Acquired Amegakaryocytic Thrombocytopenia
Dr. Paul J. Galardy
Pediatric Hematology Oncology | Pediatrics | Hematology Oncology
Distinguished in Acquired Amegakaryocytic Thrombocytopenia
Dr. Paul J. Galardy
Pediatric Hematology Oncology | Pediatrics | Hematology Oncology
200 1st St Sw, 
Rochester, MN 
 (72.5 mi)
507-284-2511
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Paul Galardy is a Pediatric Hematologist Oncology specialist and a Pediatrics provider in Rochester, Minnesota. Dr. Galardy and is rated as a Distinguished provider by MediFind in the treatment of Acquired Amegakaryocytic Thrombocytopenia. His top areas of expertise are Acquired Amegakaryocytic Thrombocytopenia, Burkitt Lymphoma, B-Cell Lymphoma, Non-Hodgkin Lymphoma, and Bone Marrow Transplant. Dr. Galardy is currently accepting new patients.

Distinguished in Acquired Amegakaryocytic Thrombocytopenia
Dr. Shakila P. Khan
Pediatric Hematology Oncology | Pediatrics | Hematology Oncology
Distinguished in Acquired Amegakaryocytic Thrombocytopenia
Dr. Shakila P. Khan
Pediatric Hematology Oncology | Pediatrics | Hematology Oncology
200 1st St Sw, 
Rochester, MN 
 (72.5 mi)
507-284-2511
Languages Spoken:
English, Urdu
See accepted insurances
Accepting New Patients

Shakila Khan is a Pediatric Hematologist Oncology specialist and a Pediatrics provider in Rochester, Minnesota. Dr. Khan and is rated as a Distinguished provider by MediFind in the treatment of Acquired Amegakaryocytic Thrombocytopenia. Her top areas of expertise are Renal Vein Thrombosis, Acquired Amegakaryocytic Thrombocytopenia, Histiocytosis, Reticulohistiocytoma, and Bone Marrow Transplant. Dr. Khan is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Distinguished in Acquired Amegakaryocytic Thrombocytopenia
Dr. Margaret L. Macmillan
Pediatric Hematology Oncology | Hematology | Oncology
Distinguished in Acquired Amegakaryocytic Thrombocytopenia
Dr. Margaret L. Macmillan
Pediatric Hematology Oncology | Hematology | Oncology
2450 Riverside Ave Se, East Building Journey Clinic 9e, 
Minneapolis, MN 
 (85.8 mi)
612-365-8100
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Margaret Macmillan is a Pediatric Hematologist Oncology specialist and a Hematologist in Minneapolis, Minnesota. Dr. Macmillan and is rated as a Distinguished provider by MediFind in the treatment of Acquired Amegakaryocytic Thrombocytopenia. Her top areas of expertise are Congenital Aplastic Anemia, Fanconi Anemia, Graft Versus Host Disease (GvHD), Aplastic Anemia, and Bone Marrow Transplant. Dr. Macmillan is currently accepting new patients.

View All Doctors
What are the latest Acquired Amegakaryocytic Thrombocytopenia Clinical Trials?
MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.
MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.
Enrollment Status: Recruiting
Publish Date: June 10, 2024
Intervention Type: Drug, Radiation, Biological
Study Phase: Phase 2

Summary: A phase II trial of a reduced intensity conditioned (RIC) allogeneic hematopoietic cell transplant (HCT) with post-transplant cyclophosphamide (PTCy) for idiopathic severe aplastic anemia (SAA), paroxysmal nocturnal hemoglobinuria (PNH), acquired pure red cell aplasia (aPRCA), or acquired amegakaryocytic thrombocytopenia (aAT) utilizing population pharmacokinetic (popPK)-guided individual dosing o...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Allogeneic Stem Cell Transplantation for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion - NYMC 588
Allogeneic Stem Cell Transplantation for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion - NYMC 588
Enrollment Status: Recruiting
Publish Date: October 26, 2023
Intervention Type: Drug
Study Phase: Phase 2

Summary: Children, adolescents, and young adults with malignant and non-malignant conditionsundergoing an allogeneic stem cell transplantation (AlloSCT) will have the stem cells selected utilizing α/β CD3+/CD19+ cell depletion. All other treatment is standard of care.

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 10, 2022
Published By: Genetic and Rare Diseases Informnation Center